CASI Pharmaceuticals (CASIF) Shares Outstanding (2021 - 2025)

CASI Pharmaceuticals (CASIF) has 5 years of Shares Outstanding (Entity) data on file, last reported at $1.9 million in Q4 2025.

• Quarterly Shares Outstanding (Entity) rose 20.85% year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (up 20.85% YoY) and the FY2025 annual result came in at $1.9 million, up 20.85% from the prior year.
• Shares Outstanding (Entity) climbed to $1.9 million in Q4 2025, from $1.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $1.9 million in Q4 2025 to a low of $1.3 million in Q1 2023.
• A 5-year average of $1.4 million and a median of $1.4 million in 2022 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) dropped 3.31% — and 2025, when it advanced 20.85%.
• Tracing CASIF's Shares Outstanding (Entity) over 5 years: stood at $1.4 million in 2021, then increased by 0.27% to $1.4 million in 2022, then retreated by 2.11% to $1.3 million in 2023, then increased by 14.82% to $1.5 million in 2024, then grew by 20.85% to $1.9 million in 2025.
• The last three Shares Outstanding (Entity) figures came in at $1.9 million (Q4 2025), $1.6 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.